New Crosslinking Agent from LANXESS for Green Tires

Vulcuren, the crosslinking agent from LANXESS, is not just a valuable crosslinker and anti-reversion agent for the manufacture of energy-saving “green tires”.

It is also an alternative to the secondary accelerator N,N’ diphenylguanidine (DPG), say experts in LANXESS’ Rubber Chemicals business unit. DPG is widely used in the manufacture of fuel-saving silicon tires, but is not suitable in combination with silanes such as Si 363. Furthermore, DPG can give off aniline under vulcanization conditions. Vulcuren does not exhibit this effect, which many customers do not want.

“Consumers around the world are becoming increasingly aware of the important role that tires play in reducing the fuel consumption of automobiles,” explains Dr. Thomas Brackemeyer, Head of Global Product Management Specialty Products in LANXESS’ Rubber Chemicals business unit. “Tire development is influenced, among other things, by the tire labeling system soon to be introduced in Europe. At present, only green tires with silicon technology are expected to achieve good classifications. Formulation development is very innovative in this area.”

In the production of “green tires”, the hybrid crosslinker Vulcuren from the Leverkusen-based specialty chemicals group has already earned a good reputation as a very balanced anti-reversion agent and a scorch-proof secondary accelerator. Vulcuren optimizes vulcanization during tire manufacture and also functions as an anti-reversion agent to improve product performance. It generates thermally stable carbasulfane crosslinks in the elastomer matrix that are not subject to the typical rearrangement reactions of vulcanizates that are crosslinked with sulfur.

“In high-performance tires, for example, this additive provides effective protection against the slow hardening of SSBR rubber, which, with increasing age, can have a negative impact on, among other things, the product’s wet grip properties,” says Brackemeyer. In its function as a secondary accelerator, Vulcuren also supports the development of tires with low rolling resistance based on silanes such as Si 363. “In the course of this development work, it is expected that Vulcuren will replace N,N’ diphenylguanidine as an established secondary accelerator. Thanks to its compatibility with the other ingredients in the rubber formulation, Vulcuren represents an excellent alternative to N,N’ diphenylguanidine,” explains Brackemeyer.

In replacing N,N’ diphenylguanidine as the secondary accelerator in silicon tread mixes, Vulcuren offers two additional benefits – it opens up new opportunities for innovative silanes in the development of advanced tires, and prevents the release of aniline under vulcanization conditions. “Vulcuren and DPG are based on two completely different kinds of chemistry. For users who are aware of the aniline problem and are looking for a new secondary accelerator, Vulcuren represents a tried-and-tested alternative with an excellent track record,” continues Brackemeyer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    LANXESS Corporation. (2019, February 10). New Crosslinking Agent from LANXESS for Green Tires. AZoM. Retrieved on November 23, 2024 from https://www.azom.com/news.aspx?newsID=24071.

  • MLA

    LANXESS Corporation. "New Crosslinking Agent from LANXESS for Green Tires". AZoM. 23 November 2024. <https://www.azom.com/news.aspx?newsID=24071>.

  • Chicago

    LANXESS Corporation. "New Crosslinking Agent from LANXESS for Green Tires". AZoM. https://www.azom.com/news.aspx?newsID=24071. (accessed November 23, 2024).

  • Harvard

    LANXESS Corporation. 2019. New Crosslinking Agent from LANXESS for Green Tires. AZoM, viewed 23 November 2024, https://www.azom.com/news.aspx?newsID=24071.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.